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Background: The enzymes of the cytochrome P450 family (CYPs) play an important role in the metabolism of a
great variety of anticancer agents; therefore, polymorphisms in genes encoding for metabolizing enzymes and
drugs transporters can affect drug efficacy and toxicity.
Methods: The genetic polymorphisms of cytochrome P450 were studied in 395 patients with breast cancer by
RLFP analysis.
Results: Here, we studied the association of functionally significant variant alleles of CYP3A4, CYP3A5, CYP2B6,
CYP2C8, CYP2C9 and CYP2C19 with the clinical response to neoadjuvant chemotherapy in breast cancer patients. A
significant correlation was observed between the CYP2C9*2 polymorphism and chemotherapy resistance (OR = 4.64;
CI 95%= 1.01 – 20.91), as well as between CYP2C9*2 heterozygotes and chemotherapy resistance in women with
nodal forms of breast cancer and a cancer hereditary load (OR = 15.50; CI 95%= 1.08 – 826.12) when the potential
combined effects were examined. No significant association between chemotherapy resistance and the other
examined genotypes and the potential combined clinical and tumour-related parameters were discovered.
Conclusion: In conclusion, CYP2C9*2 was associated with neoadjuvant chemotherapy resistance (OR = 4.64; CI
95%= 1.01 – 20.91) in the population of interest.
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Individual variability in drug efficacy and toxicity resulting
in different clinical responses is common in therapeutic
areas, including breast cancer. It is an important problem
in clinical practice because it can lead to therapeutic failure
and adverse effects. A wide variety of factors may influence
drug availability and drug response, such as race, sex, diet,
differences in drug pharmacokinetics and pharmaco-
dynamics, etc. However, the importance of all of these fac-
tors is secondary to the effect of polymorphisms in drug
metabolizing enzymes, drug transporters and drug targets.
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reproduction in any medium, provided the orfunctional significance of these polymorphisms are critical
for predicting clinical outcomes [1-3].
The members of the cytochrome P450 superfamily are
involved in phase I of the xenobiotic metabolizing process.
These enzymes catalyze the oxidation of many exogenous
and endogenous compounds and are responsible for the
metabolism of approximately 90% of clinically prescribed
drugs. The CYPs are known to be involved in the metabol-
ism of many anticancer drugs, including cyclophospha-
mide, 5-fluorouracil, adreamicin, xeloda, ifosfamide,
etoposide, paclitaxel, etc. [4]. It was recently shown that
the prodrug cyclophosphamide is activated by CYP2B6,
CYP2C9 and CYP2C19 and is inactivated by CYP3A4 and
CYP3A5 [5]. Xeloda is metabolized by CYP2B6, CYP2C8
and CYP2C9, while adreamicin and methatrexane are
metabolized by CYP3A4 [4,6].
Polymorphisms in genes encoding for metabolizing
enzymes and drug transporters can affect drug efficacy andal Ltd. This is an Open Access article distributed under the terms of the Creative
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able genes and have more than 14 and 34 polymorphic
alleles, respectively (www.imm.ki.se/CYPalleles). Most of
the CYP2C9 polymorphisms are known to decrease the en-
zymatic activity of the enzyme. The CYP2C8*3, CYP2C9*2
and CYP2C9*3 polymorphic alleles frequently occur
among Caucasians and lead to non-synonymous muta-
tions, which result in decreased activity of CYP2C8 and
CYP2C9 [7]. The CYP2C8 enzyme is involved in the me-
tabolism of cyclophosphamide, ifosphamide and paclitaxel,
while CYP2C9 metabolizes cyclofosphamide, ifosphamide
and tamoxifen and activates tegafur [5,8].
At least 28 CYP2C19 variant alleles have been previously
described (www.imm.ki.se/CYPalleles), 9 of which encode
for inactive enzymes. Mutations in exon 5 (CYP2C19*2)
and exon 4 (CYP2C19*3) are the most common poly-
morphisms. Both CYP2C19*2, which causes a 40-
nucleotide deletion and a frameshift, and CYP2C19*3,
which leads to a premature stop codon, result in the pro-
duction of a truncated protein without enzymatic activity
[9]. CYP2C19 plays a role in the metabolism of the antic-
ancer drugs cyclofosphamide, ifosphamide, tamoxifen and
thalidomide [8].
CYP2B6 may have as many as 29 polymorphisms, but
only CYP2B6*5 and CYP2B6*7 are likely to be functionally
significant and result in decreased enzymatic activity
[10,11]. CYP2B6 is involved in the activation of anticancer
drugs such as cyclophosphamide and ifosphamide [5].
CYP3A is the P450 cytochrome with the widest range of
drug substrates. For the majority of people, it is also the
most abundant cytochrome in the liver. CYP3A4 activity
has a wide range of individual activity, up to a 40-fold dif-
ference, which may be related to the individual’s health sta-
tus, environment, hormones or genetics. Over 30 CYP3A4
alleles have been described, including 18 associated, non-
synonymous mutations (www.imm.ki.se/CYPalleles). The
most common allele is CYP3A4*2, which is found in Cau-
casians and encodes for a protein with decreased activity.
A number of upstream polymorphisms have also been
detected. The most extensively studied of these is
CYP3A4*1B. This polymorphism alters the putative tran-
scriptional regulatory element - nifidipine oxidase specific
element (NFSE), which is known to be required for the ex-
pression of CYP3A4 [12]. Although the CYP3A4*1B allele
was initially shown to result in a 1.5-fold increase in tran-
scription in vitro, subsequent reports have indicated no
change in its enzymatic activity. Currently, over 11 differ-
ent CYP3A5 alleles have been identified. Individuals homo-
zygous for the CYP3A5*3 allele appear to not express a
functional version of the CYP3A5 enzyme due to a cryptic
splice site that results in the incorporation of intronic se-
quence in the mature mRNA and the production of a trun-
cated protein due to a premature appearance of
termination codon [13]. This is important in anticancertherapies as CYP3A is involved in the metabolism of many
drugs, including cyclophpsphamide, ifosfamide, docetaxel,
paclitaxel, etoposide, irinotecan, tamoxifen, imatenib, gefe-
nitib and vinca-alkaloids [4].
We studied the association of the functionally significant
variant alleles of CYP3A4, CYP3A5, CYP2B6, CYP2C8,
CYP2C9 and CYP2C19 with the clinical response to
neoadjuvant chemotherapy in breast cancer patients.
Methods
Patients
From 1991 to 2007, 395 women (mean age of 52.00± 9.89)
with a morphologically confirmed diagnosis of breast can-
cer at stages T1-4N0-3M0 were observed at the Tomsk
Cancer Research Institute in the Tomsk Scientific Center
of the RAMS. Of these, 261 were treated with one of the
following neoadjuvant chemotherapies: CMF or CMXeloda
(Cyclophosphamide, Methotrexate and either Fluorouracil
or Xeloda), FAC (Fluorouracil, Adreamicin and Cyclophos-
phamide) and CAF or CAXeloda (Cyclophosphamide,
Adreamicin and either Fluorouracil or Xeloda). The
chemotherapeutic effect was estimated after 2–4 chemo-
therapy courses through ultrasonic scanning and mam-
mography according to the World Health Organization
criteria. Complete remission (CR) was observed when no
breast tumour; partial remission (PR) when the reduction
in the tumour area was 50-100%; and stable disease (SD)
when the tumour area was reduced 0–50, progressive
disease (PD) was recorded if the tumour area increased
or if a new lesion was detected. Complete remission was
achieved in 3% of the patients; the partial remission rate
was 47%; the stable disease rate was 46% and 4% of the
patients showed progression of the disease. The patients
were divided into two groups according to the results of
the neoadjuvant therapy; patients classified as having CR,
PR or SD formed the positive response group, while
patients classified as showing PD made up the negative
chemotherapy response group. The local ethical review
boards approved the study protocol (Protocol N3 from
08.06.2005), and all patients provided written, informed
consent before acceptance into the study in accordance
with the Declaration of Helsinki.
Genotyping
The genetic polymorphisms of cytochrome P450 were
studied in 395 patients with breast cancer by RLFP ana-
lysis. Genomic DNA was kindly provided by the Tomsk
Oncology Center SB RAMS. Oligonucleotide primers for
the CYP2B6*5, CYP2C8*2, CYP2C8*3, CYP2C19*2 and
CYP2C19*3 polymorphisms and restriction endonucleases
were designed using the program Vector NTI 8.0. The pri-
mers for the CYP2C9*2, CYP2C9*3, CYP3A4*2, CYP3A4*B
and CYP3A5*3 polymorphisms were described earlier [14-
17]. All of the primer sequences are provided in Table 1.
Table 1 Primers and restriction endonucleases for the CYP450 polymorphisms genotyping
Polymorphism Oligonucleotide primers Amplicone Restriction endonucleases Restriction products, b.p.*
CYP3A5*3 (intron 3) f 5'-catcagttagtagacagatga-3' 293 Ssp I 148 125 20
r 5'-ggtccaaacagggaagaaata-3' (168 125)
CYP3A4*1B (5'-NTR) f 5'-tccaggcataggtaaagatc-3' 111 Acc 36 I 111
r 5'-aatctattaaatcgcctctcac-3' (85 26)
CYP3A4*2 (exon 6) f 5'-ttttttggatccattctttgtc-3' 124 Bst MA I 98 26
r 5'-ttttaagtggatgaattacatggt-3' (124)
CYP2C9*2 (exon 3) f 5'-cactggctgaaagagctaacagag-3' 372 Asp S9 I 179 119 74
r 5'-gtgatatggagtagggtcacccac-3' (253 119)
CYP2C9*3 (exon 7) f 5'-aggaagagattgaacgtgtga-3' 130 ERh I 130
r 5'-ggcaggctggtggggagaaggccaa-3' (104 26)
CYP2C19*2 (exon 5) f 5'-ccagagcttggcatattgta-3' 230 Sma I 109 121
r 5'-gaagcaatcaataaagtcccga-3' (230)
CYP2C19*3 (exon 4) f 5'-ctgggctgtgctccct-3' 147 BamH I 128 19
r 5'-acttggccttacctggct-3' (147)
CYB2B6*5 (exon 9) f 5'-aatacccccaacataccacatc-3' 121 Bst F5 I 105 16
r 5'-gcggggagtcagagccatt-3' (121)
CYP2C8*2 (exon 5) f 5’-aaagtaaaagaacaccaagc-3’ 167 Kzo9 I 69 65 33
r 5’- aaacatccttagtaaattaca-3’ (98 69)
CYP2C8*3 (exon 3/8) f 5’- aggcaattccccaatatctc-3’ 467 BseR I 310 111 46
r 5’-caggatgcgcaatgaagac-3’ (356 111)
* - fragments of the wild type alleles, fragments of the mutant type alleles parentheses.
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and contained 1x PCR buffer, 1–2 mM MgCl2, 250 μM
dNTPs, 0.5 μM primers, 2 U Taq DNA polymerase (Medi-
gen, Russia) and 30 ng of genomic DNA. Thermal cycling
was performed using an initial denaturation time of 3 min
at 94°C followed by 33 cycles of 15 s at 94°C, 30 s at 55°C
and 30 s at 72°C. A terminal extension time of 5 min at 72°
C was used. The reaction products were digested with the
appropriate restriction endonucleases (SibEnzyme Ltd.,
Russia) (Table 1) for 6 hour at 37°C. The fragments were
resolved by PAGE on 10% TBE gels and were subsequently
stained with ethidium bromide (10 mg/ml) to visualize the
bands using the “VersaDoc System” (Bio-Rad, USA).
Statistical analysis
The allelic and genotype frequencies for all examined
genes were calculated for descriptive purposes, and correl-
ation analyses were performed to investigate the relation-
ship between the genotypes and the neoadjuvant
chemotherapy outcome. The data were analyzed using
EpiInfo 6.0. Differences in the distributions of the variables
were analyzed by the χ2 or Fisher’s exact tests, where the
cell numbers were less than 5. We also calculated the odds
ratios (OR), 95% confidence intervals (CI) and the levels of
significance. A p value less than or equal to 0.05 was con-
sidered statistically significant. All of the genotype distribu-
tions were analyzed for Hardy-Weinberg equilibrium.Results and discussion
The distribution of the cytochrome P450 genotypes and
allele frequencies in the breast cancer patients
The cytochrome P450 genetic polymorphisms CYP2C8*2,
CYP2C8*3, CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3,
CYP3A4*1B, CYP3A4*2, CYP3A5*3 and CYP2B6*5 were
investigated in 395 female breast cancer patients. Table 2
shows the distribution of the cytochrome P450 genotypes
and allele frequencies in the patients. The distribution of
the genotype frequencies in breast cancer patients is in
agreement with the expected frequencies for the majority
of the investigated polymorphisms. Significant deviation
from Hardy-Weinberg equilibrium was observed for
CYP2C19*2 (p= 0.003) and CYP2B6*5 (p= 0.0008). This
may be indicative of the functional significance of this
locus or the variants being in non-equilibrium, linking this
locus to breast cancer.
The frequencies of the CYP2C8*2 and CYP2C8*3 mutant
alleles were 0.39% and 8.33% in the investigated group of
breast cancer patients. According to the literature, the
CYP2C8*2 allele is known to be found only in African
Americans, which carry the allele at a frequency of 18%,
while the CYP2C8*3 mutant allele occurs primarily in Cau-
casians at a frequency of 13%. Neither allele has so far been
identified in Asians [18,19].
In this group of breast cancer patients the frequency of
the CYP2C9*2 and CYP2C9*3 mutant alleles was 10.36%
Table 2 Genotype and allele frequencies of the CYP P450 genes in breast cancer patients
Nomenclature rs Nucleotide changes Effect n Genotype frequencies, % Allele frequencies, %
wt ht vt p q
CYP2C8*2 rs11572103 T805A I269F 383 99.22 0.78 0.00 99.61 0.39
CYP2C8*3 rs11572080+ rs10509681 G416A+ A1196G R139K + K399R 390 83.85 15.64 0.51 91.67 8.33
CYP2C9*2 rs1799853 C430T R144C 391 79.54 20.20 0.26 89.64 10.36
CYP2C9*3 rs1057910 A1075C I359L 394 81.22 17.77 1.02 90.10 9.90
CYP2C19*2 rs4244285 G681A Splicing defect 393 58.52 39.19 2.29 78.12 21.88
CYP2C19*3 rs4986893 G636A W212X 388 97.94 2.06 0.00 98.97 1.03
CYP3A4*1B rs2740574 A-392 G 5'NTO change 389 94.86 5.14 0.00 97.43 2.57
CYP3A4*2 rs55785340 T664C S222P 391 100.00 0.00 0.00 100.00 0.00
CYP3A5*3 rs776746 A6986G R487C 392 0.26 11.99 87.76 6.25 93.75
CYP2B6*5 rs3211371 C1459T Splicing defect 390 85.64 12.56 1.79 91.92 8.08
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number found in the literature for Caucasians, i.e., 8-19%
and 0–8.5% [1,7,20-23] for CYP2C9*2 and CYP2C9*3, re-
spectively, but it is significantly higher than that found in
African Americans, who carry the alleles at a frequency of
1% and 0.5%, respectively. The CYP2C9*2 allele has not
been detected in a Chinese population, and the frequencyTable 3 Distribution of CYP2 genotypes and risk of neoadjuv
patients
Polymorphism Genotype Positive neoadjuvant
chemotherapy response
n %
CYP2B6*5 C1459T CC 205 82.66
CT 37 14.92
TT 6 2.42
CYP2C8*2 T805A TT 243 99.59
TA 1 0.41
AA 0 0.00
CYP2C8*3 G416A+A1196G GG 203 82.19
GA 44 17.81
AA 0 0.00
CYP2C9*2 C430T CC 204 82.26
CT 44 17.74
TT 0 0.00
CYP2C9*3 A1075C AA 211 84.40
AC 36 14.40
CC 3 1.20
CYP2C19*2 G681A GG 136 54.62
GA 109 43.78
AA 4 1.61
CYP2C19*3 G636A GG 241 97.97
GA 5 2.03
AA 0 0.00
*- OR, CI (95%) and p-values were not applicable to these samples.of the CYP2C9*3 allele was 2–2.6% [22,24]. The
CYP2C19*2 mutant allele was found at a frequency of
21.9% in this study, which is not significantly different from
previous reports in the literature for Caucasians (15 20%)
[1,7] and Japanese (26.7%) [25]. The CYP2C19*3 mutant
allele frequency was 1.03% in our group of breast cancer
patients, which was not different from the value found inant chemotherapy resistance developing in breast cancer
Negative neoadjuvant
chemotherapy response
OR CI (95%) p
n %
9 90.00 1.89 0.25 - 84.64 0.99
1 10.00 1.13 0.54 - 2.40 0.99
0 0.00 0.63 0.01 - 4.82 0.99
10 100.00 0.04 0.01 - 3.55 0.08
0 0.00 24.30 0.28 - 1914.18 0.08
0 0.00 *
6 60.00 0.33 0.07 - 1.64 0.09
4 40.00 3.08 0.61 - 13.53 0.09
0 0.00 *
5 50.00 0.22 0.05 - 0.99 0.02
5 50.00 4.64 1.01 - 20.91 0.02
0 0.00 *
8 80.00 0.74 0.14 - 7.41 0.66
1 10.00 0.66 0.01 - 5.03 0.99
1 10.00 9.15 0.16 - 124.95 0.15
8 66.67 3.32 0.64 - 32.61 0.19
2 16.67 0.32 0.03 - 1.66 0.20
2 16.67 6.13 0.11 - 69.01 0.20
10 100.00 0.21 0.02 - 10.78 0.23
0 0.00 4.82 0.09 - 48.97 0.23
0 0.00 *
Table 4 Distribution of CYP3 genotypes and risk of neoadjuvant chemotherapy resistance developing in breast cancer
patients




OR CI (95%) p
n % n %
CYP3A4*1B A-392 G AA 234 94.74 9 90.00 0.04 0.01 - 3.47 0.08
AG 13 5.26 1 10.00 24.90 0.29 - 1961.25 0.08
GG 0 0.00 0 0.00 *
CYP3A4*2 T664C TT 249 100.00 10 100.00 *
TC 0 0.00 0 0.00 *
CC 0 0.00 0 0.00 *
CYP3A5*3 A6986G AA 0 0.00 0 0.00 *
AG 33 13.31 1 10.00 0.72 0.02 - 5.53 0.99
GG 215 86.69 9 90.00 1.38 0.18 - 62.36 0.99
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[26]. This allele occurs only in heterozygocity. None of the
investigated patients were homozygotes for the CYP2C19*3
allele. The CYP2B6*5 mutant allele frequency was 8.1%,
which was not significantly lower than the published value
for Caucasians (9.1%) and higher than that published for
Asians (4.2%).
The frequency of the CYP3A4*1B mutant allele was
2.57% in this group of breast cancer patients; the literature
reports significant interethnic variations in this allele (2-9%
for Caucasians, 35-66% for African Americans and 0% for
Taiwanese and Chinese [27]). The CYP3A4*2 mutant allele
was not present in the investigated group of breast cancer
























*- OR, CI(95%) and p-values were not applicable to these samples.patients, while in its frequency in Caucasians ranges from
1.1% in a German population to 4.5% in a Portuguese
population [28].
The frequency of the CYP3A5*3 polymorphic allele in
the total population sampled was 93.75%. This agrees with
the previously published data, which reports a total fre-
quency of the CYP3A5*3 allele of 91.7- 94.2% in Cauca-
sians [14,27,29] and 66.7-75% in Asians [30].
The cytochrome P450 polymorphisms and the
chemotherapy efficacy in the breast cancer patients
Table 3 shows the distribution of the polymorphic variants





OR CI (95%) p
% n %
1.76 7 70.00 4.77 0.71 - 23.47 0.055
8.24 3 30.00
3.52 2 40.00 0.13 0.01 - 1.29 0.04
6.48 3 60.00 7.60 0.78 - 95.24 0.04
0.00 0 0.00 *
1.83 10 71.43 4.50 0.97 - 16.60 0.027
8.17 4 28.57
3.66 3 42.86 0.15 0.02 - 0.92 0.019
6.34 4 57.14 6.83 1.09 - 48.12 0.019
0.00 0 0.00 *
1.89 3 50.00 11.33 1.32 - 91.23 0.01
8.11 3 50.00
3.78 0 0.00 0.06 0.01 - 0.91 0.02
6.22 3 100.00 15.50 1.08 - 826.12 0.02
0.00 0 0.00 *
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for the CYP2 family. The study of the association of the
CYP2B6*5, CYP2C8*2, CYP2C8*3, CYP2C9*2, CYP2C9*3,
CYP2C19*2 and CYP2C19*3 variants with a negative re-
sponse to neoadjuvant chemotherapy in breast cancer
patients included an odds ratio evaluation indicating the
probability of poor chemotherapeutic efficacy in indivi-
duals with certain genotypes. The observed distribution of
the most common genotypes in breast cancer patients are
in Hardy-Weinberg equilibrium with the exception of
CYP2B6*5 (p = 0.0198) and CYP19*2 (p= 0.0003). The
enrichment of the CYP2B6*5 and CYP19*2 alleles in
this group may be due to the population possessing
its own pool of alleles, resulting in different frequen-
cies of unfavorable alleles. The risk of an insufficient
response to breast cancer neoadjuvant chemotherapy
in CYP2C9*2 heterozygotes was 4.64-fold higher (OR =
4.64, p = 0.02) than in patients with the wild type
allele. The impaired efficacy of neoadjuvant chemo-
therapy in patients containing the CYP2C9*2 mutant
allele might be a result of the enzymatic activity of
CYP2C9, which is involved into the chain reaction re-
sponsible for the conversion of the cyclophpsphamide
prodrug into an active metabolite [29,30].
The risk of poor neoadjuvant chemotherapy efficacy is
much higher in CYP2C8*2 heterozygotes (OR= 24.30) and
slightly higher in CYP2C8*3 heterozygotes (OR=3.08) at a
level of statistical significance close to the proposed level
(p = 0.08 and p=0.09, respectively, versus p< 0.05). Fur-
thermore, the CYP2C9*3 (OR=9.15) and CYP2C19*2
(OR=6.13) mutant type genotypes and heterozygotic
CYP2C19*3 (OR=4.82) genotype are associated with a low
efficacy of neoadjuvant chemotherapy; however, these asso-
ciations were not found to be statistically significant
(p> 0.05). It appears that the CYP2B6*5, CYP2C8*2,
CYP2C8*3, CYP2C9*3, CYP2C19*2 and CYP2C19*3 mu-
tant alleles are not a factor in resistance to neoadjuvant
chemotherapies in breast cancer patients.
Table 4 shows the distribution of the polymorphic var-
iants of the genes studied here in breast cancer patients
along with the known efficacy of the neoadjuvant chemo-
therapy for the CYP3 family. Gene polymorphisms asso-
ciation with neoadjuvant chemotherapy efficacy were
analyzed for the CYP3A4*1B and CYP3A5*3 polymorph-
isms. CYP3A4*2 was not included in the study because
no heterozygotes or homozygotes containing the
CYP3A4*2 mutant allele were found in the population.
For CYP3A4*1B heterozygotes, the risk of a negative re-
sponse to neoadjuvant chemotherapy is 24.9-fold higher
than in carriers of the wild type allele, which has a level
of significance (p = 0.08) that approaches the significance
threshold (p = 0.05). No significant association between
CYP3A5*3 genotypes and chemotherapy resistance were
discovered.The analyses performed here cover the distribution of
cytochrome genetic polymorphisms and their association
with the known efficacy of neoadjuvant chemotherapy in
breast cancer patients known to have a cancer hereditary
load (cancer cases in patient’s relatives), a clinical form of
cancer, degree of malignancy and histological type of
tumour. In CYP2C9*2 heterozygotes with a high hereditary
load, the risk of tumour resistance to neoadjuvant chemo-
therapy was 7.6-fold higher than wild type homozygotes
(OR=7.6, p= 0.04) (Table 5). A similar association was
observed in patients with the nodal form of breast cancer.
The risk of tumour resistance to chemotherapy for
CYP2C9*2 heterozygotes was 6.83-fold higher than in wild
type homozygotes (Table 5; OR=6.83, p = 0.019). In
CYP2C9*2 heterozygotes with nodal form of cancer and a
cancer hereditary load, the risk of resistance to chemother-
apy was 15.5-fold higher than those with the wild type
genotype (OR=15.5, p= 0.02). Patients with other clinical
features and genetic variants of the investigated cyto-
chromes showed no statistically important association with
neoadjuvant chemotherapy efficacy.
Conclusions
CYP2C9*2 polymorphism is associated with neoadjuvant
chemotherapy efficacy in breast cancer patients (OR=4.64;
CI 95%=1.01 – 20.91).
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